Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

BACKGROUND: Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as neoadjuva...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin, Jiang, Hongchuan, Zhang, Jian, Bao, Guoqiang, Zhang, Guoqiang, Wang, Haibo, Wang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650529/
https://www.ncbi.nlm.nih.gov/pubmed/34872507
http://dx.doi.org/10.1186/s12885-021-09050-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650529/
https://www.ncbi.nlm.nih.gov/pubmed/34872507
http://dx.doi.org/10.1186/s12885-021-09050-6

Ejemplares similares